Our mission
Paving the Way to an Efficient and Sustainable Future of Adherent Cell Cultivation –
for People
and the Planet
Healthy people:
Enabling patient access
New therapies become approved in a fast-paced manner, but how accessible are these to patients?
Cell and Gene Therapy (CGT) costs up to $4.25 m per dose.¹ A price tag that most patients are not able to cover themselves or have paid by their health insurance. Advanced therapies are therefore not accessible for everyone.
In Cell & Gene Therapy, manual labor causes up to 71% of production costs.² Manufacturing therapies includes a complex and intensive cell cultivation process.
Innovating scalable systems for adherent cell culture, like the CellScrew®, is key to increase patient access and affordability to life-changing novel therapies.
400 million people are affected by rare diseases³
2x more approved therapies since 2013 in the Cell and Gene Therapies sector⁴
Healthy planet: Cutting carbon emissions
Healthy people need a healthy planet. Aiming to help people and treat diseases, the healthcare sector produces 55% more greenhouse gas (GHG) emissions than the automotive industry.⁷
The industry produces massive amounts of plastic waste and accounts for 4.4% of the global net carbon emissions⁸, harming the environment we live in and rely on. More than ever before, it is obvious that limiting temperature rise by reducing emissions is essential for preventing further damage to the health of our planet and ourselves. How can we reduce the impact of our healthcare system?
Being the pioneering company for the production of labware from plant-based plastic, we empower the biopharmaceutical industry to embrace sustainability.
Our contribution to the sustainable development goals
While single-use equipment made of non-renewable plastics improves efficiency, it impedes sustainability. Our product, the CellScrew®, addresses this by providing sustainable, technically advanced alternatives. It reduces manual labor, production materials, cleanroom space, plastic waste, and CO₂ emissions.
Hear about our vision in one of these videos
Or meet us at an upcoming event!
Meet us at our booth from Sep 8-9 to examine and test out our novel products.
Meet us at our booth from Sep 9-11 to explore our latest data and collaboration progress.
Company updates
Green Elephant Biotech secures INNOWWIDE Grant to test automated adherent MSC manufacturing for the U.S. market
Green Elephant Biotech has secured an INNOWWIDE market feasibility grant from the German Federal Ministry of Research, Technology and Space (BMFTR). The grant funds a feasibility study, “Automation4MSC”, running from … Read more
Green Elephant Biotech is a partner in S.O.L.A.R.I.S. advancing scalable and sustainable CAR T cell manufacturing across Europe
S.O.L.A.R.I.S., a new EU-funded project by Horizon Europe, will develop and test novel approaches to CAR T cell manufacturing to improve patient access to therapies across Europe.
